Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.44 |
| ▸ | FABP1 | P07148 | 3/20 | 0.40 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28320904 | 0.88 | NR1H4 (0.46) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL19689512 | 0.88 | NR1H4 (0.46) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL12168751 | 0.83 | NR1H4 (0.47) | NR1H4 | |
| SCHEMBL12168749 | 0.83 | NR1H4 (0.55) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL21216847 | 0.83 | NR1H4 (0.45) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL19705737 | 0.81 | NR1H4 (0.47) | NR1H4FABP1HSD17B13 | |
| SCHEMBL24565512 | 0.80 | NR1H4 (0.46) | NR1H4FABP1HSD17B13 | |
| SCHEMBL28870286 | 0.80 | NR1H4 (0.43) | NR1H4FABP1HSD17B13 | |
| SCHEMBL12168750 | 0.80 | NR1H4 (0.40) | NR1H4FABP1HSD17B13FABP4 | |
| SCHEMBL28241510 | 0.79 | NR1H4 (0.43) | NR1H4FABP1FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691553-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4534536-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-3746448-B1 | NITROGENOUS TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-113302190-B | FXR (NR 1H 4) modulating compounds | 吉利德科学公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4089072-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4360632-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117924266-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924267-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-109476636-B | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| CN-109476636-A | Compounds that modulate FXR (NR1H4) | 吉利德科学公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885FABP1 15/4885HSD17B13 707/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885FABP1 15/4885HSD17B13 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.